Grob CS
UCLA Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, United States of America; The Lunquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center, United States of America.
ArticlePsilocybin
Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial.
ArticleMDMA
A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.
ArticlePsilocybin
A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.
ArticlePsilocybin
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research.
ArticlePsilocybin
Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution.
ArticlePsilocybin
Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.
ArticlePsilocybin
Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development.
ArticlePsilocybin
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.
ArticlePsilocybin
If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.
ArticlePsychedelics